Blog

  • Training: Building to Bayer Leverkusen clash – Manchester City FC

    1. Training: Building to Bayer Leverkusen clash  Manchester City FC
    2. 24-man Manchester City squad spotted in training ahead of Bayer Leverkusen clash  City Xtra
    3. Pep Guardiola apology as Rodri injury update given and Claudio Echeverri Man City hint…

    Continue Reading

  • New Ultra Wonder Collection Brings Premium Multi-Tasking Curl Care to Mass Market

    CINCINNATI–(BUSINESS WIRE)–Aussie is redefining curl care with the launch of Ultra Wonder, breaking the rules and challenging the notion that great hair requires a dozen products and hours of styling. As the brand’s first premium innovation, the three-product collection—Ultra Wonder Daily Mist, Ultra Wonder Treatment, and Ultra Wonder Gel Crème (each $9.99) — merges the benefits of treatments and stylers in single formulas, inviting consumers to “Dare to Wonder” and simplify their routines without sacrificing performance.

    The Collection: Three Multi-Benefit Curl Care Products

    Streamlined formulas powered by amino acids and strengthening lipids replace multiple products while delivering treatment-level care for visibly healthier, more defined hair.

    • Ultra Wonder Daily Mist (MSRP $9.99): An all-in-one, multi-tasking mist that primes, protects, detangles, conditions, and adds shine, leaving hair 55% more glossy*. Transforms from a silky cream to a lightweight spray with 450°F heat protection and anti-breakage benefits. Silicone-free and designed for daily use.
    • Ultra Wonder Treatment (MSRP $9.99): A sulfate-free rich treatment made with amino acids that makes hair 3x stronger** and protects against breakage. Multi-tasking formula delivers strengthening moisture and bond repair – in or out of the shower – with 48H bond protection and 24H moisturization.
    • Ultra Wonder Gel Crème (MSRP $9.99): The hold and styling power of a gel meets the moisture of a cream. Made with strengthening lipids and amino acids while being paraben-free. Delivers 24H curl definition and 24H frizz control, even in high humidity. Perfect for slick-backs, taming fly-aways and edges, defining curls, or refreshing protective styles.

    “We’re thrilled to introduce Ultra Wonder — born from a simple truth: great curls shouldn’t demand a dozen products or a complicated routine,” said Eryn Lampkin, Brand Director Aussie, Multicultural Hair. “Each formula works harder so you don’t have to, from our Daily Mist that primes, protects, detangles, and conditions in one step, to our Treatment that delivers bond repair and deep moisture in or out of the shower. Premium performance doesn’t require a premium price — every product is under $10, giving you back time, money, and confidence in your curl care.”

    Accessible Innovation for Curly Hair Textures

    Ultra Wonder delivers Aussie’s commitment to innovation, flexibility, and high-performance hair care at an accessible price point. These multi-taskers combine multiple products and benefits into one, giving consumers ultimate flexibility to simplify their routines without sacrificing results — designed for every texture, every lifestyle, and every unique hair journey.

    Ultra Wonder will be available on Amazon, TikTok Shop and at food, drug, and mass market retailers nationwide.

    Instagram: @AussieHaircare
    TikTok: @AussieHaircare

    *vs non-conditioning shampoo

    **vs non-conditioning shampoo/strength against breakage

    About Aussie Haircare

    Aussie Haircare strives to bring the fun into haircare with a diverse lineup of products. Aussie Hair has a variety of shampoos, conditioners, and styling products for all hair types to help you look and feel your best every day. The current Aussie Hair offerings include: Ultra Wonder, 3 Minute Miracle, Miracle Coils, Miracle Waves, Hair Insurance, Instant Freeze, Mega, Instant Volume, Miracle Curls, Miracle Moist, Miracle Repairer, Sprunch, Total Miracle and more. All Aussie products are PETA certified cruelty-free.

    About Procter & Gamble

    P&G serves consumers around the world with one of the strongest portfolios of trusted, quality, leadership brands, including Always®, Ambi Pur®, Ariel®, Bounty®, Charmin®, Crest®, Dawn®, Downy®, Fairy®, Febreze®, Gain®, Gillette®, Head & Shoulders®, Lenor®, Olay®, Oral-B®, Pampers®, Pantene®, SK-II®, Tide®, Vicks®, and Whisper®. The P&G community includes operations in approximately 70 countries worldwide. Please visit https://www.pg.com for the latest news and information about P&G and its brands. For other P&G news, visit us at https://www.pg.com/news.

    Contacts

    For more information on Ultra Wonder and the latest innovations from Aussie, please contact:

    Jess Diah

    jdiah@devriesglobal.com


    Continue Reading

  • Stock set to win from thaw in China-U.S. relations, Amazon’s AI project

    Stock set to win from thaw in China-U.S. relations, Amazon’s AI project

    Continue Reading

  • Scientists Unveil Detailed View of Stress Protein

    Scientists Unveil Detailed View of Stress Protein

    In an effort to reveal the inner workings of a protein that serves as a cell’s damage detection system, scientists at Johns Hopkins and the Ludwig-Maximilians-University Munich (LMU) have published what is believed to be the first 3D…

    Continue Reading

  • New Moms' GLP-1 Prescriptions Jumped After Wegovy Approval – MedPage Today

    1. New Moms’ GLP-1 Prescriptions Jumped After Wegovy Approval  MedPage Today
    2. Discontinuing GLP-1s Before or Early in Pregnancy Tied to Weight Gain, Pregnancy Complications  The American Journal of Managed Care® (AJMC®)
    3. How does stopping weight loss…

    Continue Reading

  • National Trends and Impact of the COVID-19 Pandemic on Trauma Patient Care in the United States

    National Trends and Impact of the COVID-19 Pandemic on Trauma Patient Care in the United States

    Continue Reading

  • Immune Priming Strategies Numerically Improve PFS in Ovarian Cancer

    Immune Priming Strategies Numerically Improve PFS in Ovarian Cancer

    Priming strategies with olaparib (Lynparza), including the addition of durvalumab (Imfinzi) with or without low-dose cyclophosphamide (LDCy), did not definitively improve efficacy outcomes vs olaparib monotherapy among patients with platinum-sensitive recurrent ovarian cancer (PSROC), according to findings from the non-comparative phase 2 SOLACE2 trial (ACTRN12618000686202) published in Nature Communications.

    After a median follow-up of 44.7 months (range, 1-47), the 36-week progression-free survival (PFS) rates among patients treated with olaparib/durvalumab in arm A (n = 38), olaparib/durvalumab/LDCy in arm B (n = 39), and olaparib alone in arm C (n = 37), were 47.4% (95% CI, 31.0%-62.1%), 48.7% (95% CI, 32.5%-63.2%), and 35.1% (95% CI, 20.4%-50.3%), respectively. Additionally, the median PFS among the respective arms was 35.6 weeks (95% CI, 23.6-40.4), 35.9 weeks (95% CI, 23.7-48.1), and 24.4 weeks (95%, CI 22.1-36.1)

    Regarding responses, the confirmed objective response rate (ORR) per RECIST v1.1 criteria and the Gynecologic Cancer Intergroup (GCIG) in arms A, B, and C was 42.1% (95% CI, 26.3%-59.2%), 53.8% (95% CI, 37.2%-69.9%), and 35.1% (95% CI, 20.2%-52.5%).

    “[O]laparib/durvalumab and olaparib/LDCy/durvalumab were associated with numerically greater ORR and longer PFS as compared with olaparib monotherapy but this study was not powered for relative comparison between treatment arms. Most importantly, we characterized concise immunological features of study [patients] who benefitted the most from these olaparib-based therapies, including in the homologous recombination proficient [HRP] and BRCA wild-type subgroups,” lead study author Chee Khoon Lee, from the NHMRC Clinical Trials Centre of The University of Sydney and the Department of Medical Oncology at St George Hospital in Kogarah, New South Wales, Australia, wrote with coauthors. “Ongoing work will continue to better identify patients and treatment strategies to optimally incorporate PARP [inhibitors] and [immune checkpoint inhibitors] into the treatment paradigm for PSROC.”

    Among patients with confirmed human recombinant deficient (HRD) disease (n = 71), the 36-week PFS rates in arms A, B, and C were 59.1% (95% CI, 36.1%-76.2%), 56.0% (95% CI, 34.8%-72.3%), and 37.5% (95% CI, 19.0%-56.0%); for patients with HRP disease (n = 29), the rates were 40.0% (95% CI, 12.3%-67.0%), 40.0% (95% CI, 12.3%-67.0%), and 22.2% (95% CI, 3.4%-51.3%) in the respective arms. Additionally, a significant difference in PFS was observed between the HRD and HRP subgroups across all treatment arms (HR, 0.55; 95% CI, 0.35-0.87; P = .01).

    Moreover, the confirmed ORR in arms A, B, and C, respectively, in the HRD population was 57.9% (95% CI, 33.5%-79.7%), 63.6% (95% CI, 40.7%-82.8%), and 36.4% (95% CI, 17.2%-59.3%); for the HRP population, the respective rates were 22.2% (95% CI, 2.8%-60.0%), 40.0% (95% CI, 12.2%-73.8%), and 14.3% (95% CI, 0.4%-57.9%).

    The multicenter phase 2 study was conducted across 15 hospitals in Australia. Those with histologically confirmed high-grade serous ovarian cancer who underwent prior surgery and received at least 1 line of platinum-based chemotherapy were eligible for enrollment. Patients must also have had PRSOC, asymptomatic or minimally symptomatic disease, raised CA-125 levels, and/or measurable disease.

    Patients enrolled were randomly assigned 1:1:1 to receive olaparib/durvalumab, olaparib/durvalumab/LDCy, and olaparib alone. All patients across arms received 300 mg of olaparib twice daily continuously. In the priming phase, arm B received oral LDCy at 50 mg on days 1 to 5 every week. In the consolidation phase, the same regimen of olaparib was maintained, but those in arms A and B of treatment received a fixed dose of durvalumab at 1500 mg once every 28 days for a maximum of 3 years.

    Treatment in all arms continued in the absence of disease progression, unacceptable toxicity, or withdrawal from study. Additionally, olaparib or durvalumab treatment could be continued beyond radiological progression.

    In arm A, B, and C, the median age was 65 years (range, 42-83), 63 years (range, 44-81), and 72 years (range, 46-87), respectively. A total of 81.6%, 82.1%, and 73.0% had an ECOG performance status of 0; 84.2%, 79.5%, and 59.5% had primary ovarian cancer; and 57.9%, 64.1%, and 73.0% had FIGO stage III disease at diagnosis. Most patients in each arm had measurable disease (71.1%, 71.8%, and 70.3%), HRD BRCA wild-type disease (50.0%, 51.3%, 51.4%), and a platinum-free interval of more than 12 months (65.8%, 61.5%, 64.9%).

    The primary end point of the study was the 36-week PFS rate. Key secondary end points included ORR per RECIST v1.1 criteria and GCIG CA-125, patient-reported outcomes, time to next therapy, and safety.

    In the priming phase of the study, grade 3 or higher adverse effects (AEs) were observed in 15.8% of arm A, 43.6% of arm B, and 21.6% of arm C. In the consolidation phase, the respective grade 3 rates were 37.8%, 48.6%, and 40.0%. The most commonly reported AEs included nausea, fatigue, and anemia.

    One grade 3 or higher immune-related AE was observed in a single patient in arm B. In the priming phase, 5.3%, 12.8%, and 5.4% of the respective arms experienced AEs leading to dose interruption in addition to 5.4%, 8.6%, and 13.3% who experienced AE-related interruptions in the consolidation phase.

    Reference

    Lee CK, Kartikasari AE, Bound NT, et al. Olaparib, durvalumab, and cyclophosphamide, and a prognostic blood signature in platinum-sensitive ovarian cancer: the randomized phase 2 SOLACE2 trial. Nat Commun. 2025;16(9756). doi:10.1038/s41467-025-64130-6

    Continue Reading

  • ARISE OVERDRIVE LAUNCHES TODAY ON STEAM AND XBOX PC

    ARISE OVERDRIVE LAUNCHES TODAY ON STEAM AND XBOX PC

    Launch Trailer Drops, Featuring Sung Jinwoo’s Ascension to Become the Ultimate Monarch of Shadows

    SEOUL, South Korea, Nov. 24, 2025 /PRNewswire/ — Solo Leveling: ARISE OVERDRIVE, developed by Netmarble Neo and published…

    Continue Reading

  • Introducing Claude Opus 4.5 \ Anthropic

    Introducing Claude Opus 4.5 \ Anthropic

    Our newest model, Claude Opus 4.5, is available today. It’s intelligent, efficient, and the best model in the world for coding, agents, and computer use. It’s also meaningfully better at everyday tasks like deep research and working with slides and spreadsheets. Opus 4.5 is a step forward in what AI systems can do, and a preview of larger changes to how work gets done.

    Claude Opus 4.5 is state-of-the-art on tests of real-world software engineering:

    Opus 4.5 is available today on our apps, our API, and on all three major cloud platforms. If you’re a developer, simply use claude-opus-4-5-20251101 via the Claude API. Pricing is now $5/$25 per million tokens—making Opus-level capabilities accessible to even more users, teams, and enterprises.

    Alongside Opus, we’re releasing updates to the Claude Developer Platform, Claude Code, and our consumer apps. There are new tools for longer-running agents and new ways to use Claude in Excel, Chrome, and on desktop. In the Claude apps, lengthy conversations no longer hit a wall. See our product-focused section below for details.

    First impressions

    As our Anthropic colleagues tested the model before release, we heard remarkably consistent feedback. Testers noted that Claude Opus 4.5 handles ambiguity and reasons about tradeoffs without hand-holding. They told us that, when pointed at a complex, multi-system bug, Opus 4.5 figures out the fix. They said that tasks that were near-impossible for Sonnet 4.5 just a few weeks ago are now within reach. Overall, our testers told us that Opus 4.5 just “gets it.”

    Many of our customers with early access have had similar experiences. Here are some examples of what they told us:

    Evaluating Claude Opus 4.5

    We give prospective performance engineering candidates a notoriously difficult take-home exam. We also test new models on this exam as an internal benchmark. Within our prescribed 2-hour time limit, Claude Opus 4.5 scored higher than any human candidate ever1.

    The take-home test is designed to assess technical ability and judgment under time pressure. It doesn’t test for other crucial skills candidates may possess, like collaboration, communication, or the instincts that develop over years. But this result—where an AI model outperforms strong candidates on important technical skills—raises questions about how AI will change engineering as a profession. Our Societal Impacts and Economic Futures research is aimed at understanding these kinds of changes across many fields. We plan to share more results soon.

    Software engineering isn’t the only area on which Claude Opus 4.5 has improved. Capabilities are higher across the board—Opus 4.5 has better vision, reasoning, and mathematics skills than its predecessors, and it is state-of-the-art in many domains:

    Comparison table showing frontier model performance across popular benchmarks

    The model’s capabilities outpace some of the benchmarks we use in our tests. A common benchmark for agentic capabilities is τ2-bench, which measures the performance of agents in real-world, multi-turn tasks. In one scenario, models have to act as an airline service agent helping a distressed customer. The benchmark expects models to refuse a modification to a basic economy booking since the airline doesn’t allow changes to that class of tickets. Instead, Opus 4.5 found an insightful (and legitimate) way to solve the problem: upgrade the cabin first, then modify the flights.

    Let me think about what options I have within my policy:
    
    1. Modify flights - Basic economy cannot be modified. This is clear in the policy.
    2. Change cabin - Wait, let me check this option! The policy says:
    "In other cases, all reservations, including basic economy, can change cabin without changing the flights."
    
    But he wants to change the flights, not just the cabin. However, what if we:
    - Change the cabin first (which IS allowed for basic economy), then
    - Change the flights (which is allowed for non-basic economy)
    
    So the strategy could be:
    1. Upgrade his cabin from basic economy to economy (or business)
    2. Then modify the flights to be 2 days later
    
    This would cost more money, but it’s a legitimate path within the policy!

    The benchmark technically scored this as a failure because Claude’s way of helping the customer was unanticipated. But this kind of creative problem solving is exactly what we’ve heard about from our testers and customers—it’s what makes Claude Opus 4.5 feel like a meaningful step forward.

    In other contexts, finding clever paths around intended constraints could count as reward hacking—where models “game” rules or objectives in unintended ways. Preventing such misalignment is one of the objectives of our safety testing, discussed in the next section.

    A step forward on safety

    As we state in our system card, Claude Opus 4.5 is the most robustly aligned model we have released to date and, we suspect, the best-aligned frontier model by any developer. It continues our trend towards safer and more secure models:

    In our evaluation, “concerning behavior” scores measure a very wide range of misaligned behavior, including both cooperation with human misuse and undesirable actions that the model takes at its own initiative [2].

    Our customers often use Claude for critical tasks. They want to be assured that, in the face of malicious attacks by hackers and cybercriminals, Claude has the training and the “street smarts” to avoid trouble. With Opus 4.5, we’ve made substantial progress in robustness against prompt injection attacks, which smuggle in deceptive instructions to fool the model into harmful behavior. Opus 4.5 is harder to trick with prompt injection than any other frontier model in the industry:

    Note that this benchmark includes only very strong prompt injection attacks. It was developed and run by Gray Swan.

    You can find a detailed description of all our capability and safety evaluations in the Claude Opus 4.5 system card.

    New on the Claude Developer Platform

    As models get smarter, they can solve problems in fewer steps: less backtracking, less redundant exploration, less verbose reasoning. Claude Opus 4.5 uses dramatically fewer tokens than its predecessors to reach similar or better outcomes.

    But different tasks call for different tradeoffs. Sometimes developers want a model to keep thinking about a problem; sometimes they want something more nimble. With our new effort parameter on the Claude API, you can decide to minimize time and spend or maximize capability.

    Set to a medium effort level, Opus 4.5 matches Sonnet 4.5’s best score on SWE-bench Verified, but uses 76% fewer output tokens. At its highest effort level, Opus 4.5 exceeds Sonnet 4.5 performance by 4.3 percentage points—while using 48% fewer tokens.

    With effort control, context compaction, and advanced tool use, Claude Opus 4.5 runs longer, does more, and requires less intervention.

    Our context management and memory capabilities can dramatically boost performance on agentic tasks. Opus 4.5 is also very effective at managing a team of subagents, enabling the construction of complex, well-coordinated multi-agent systems. In our testing, the combination of all these techniques boosted Opus 4.5’s performance on a deep research evaluation by almost 15 percentage points3.

    We’re making our Developer Platform more composable over time. We want to give you the building blocks to construct exactly what you need, with full control over efficiency, tool use, and context management.

    Product updates

    Products like Claude Code show what’s possible when the kinds of upgrades we’ve made to the Claude Developer Platform come together. Claude Code gains two upgrades with Opus 4.5. Plan Mode now builds more precise plans and executes more thoroughly—Claude asks clarifying questions upfront, then builds a user-editable plan.md file before executing.

    Claude Code is also now available in our desktop app, letting you run multiple local and remote sessions in parallel: perhaps one agent fixes bugs, another researches GitHub, and a third updates docs.

    For Claude app users, long conversations no longer hit a wall—Claude automatically summarizes earlier context as needed, so you can keep the chat going. Claude for Chrome, which lets Claude handle tasks across your browser tabs, is now available to all Max users. We announced Claude for Excel in October, and as of today we’ve expanded beta access to all Max, Team, and Enterprise users. Each of these updates takes advantage of Claude Opus 4.5’s market-leading performance in using computers, spreadsheets, and handling long-running tasks.

    For Claude and Claude Code users with access to Opus 4.5, we’ve removed Opus-specific caps. For Max and Team Premium users, we’ve increased overall usage limits, meaning you’ll have roughly the same number of Opus tokens as you previously had with Sonnet. We’re updating usage limits to make sure you’re able to use Opus 4.5 for daily work. These limits are specific to Opus 4.5. As future models surpass it, we expect to update limits as needed.

    Continue Reading

  • Stopping GLP-1s for Pregnancy Linked to Weight Gain, Complications – MedPage Today

    1. Stopping GLP-1s for Pregnancy Linked to Weight Gain, Complications  MedPage Today
    2. Discontinuing GLP-1s Before or Early in Pregnancy Tied to Weight Gain, Pregnancy Complications  The American Journal of Managed Care® (AJMC®)
    3. How does stopping…

    Continue Reading